FDA Accepts GSK's BLA for Blenrep Combos in Multiple Myeloma
Portfolio Pulse from
The FDA has accepted GSK's Biologics License Application (BLA) for Blenrep combinations aimed at treating relapsed/refractory multiple myeloma, with a decision expected by July 23, 2025.
November 26, 2024 | 4:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GSK's BLA for Blenrep combinations in multiple myeloma treatment has been accepted by the FDA, with a decision due by July 23, 2025.
The acceptance of the BLA by the FDA is a positive regulatory step for GSK, potentially leading to approval of Blenrep combinations for multiple myeloma. This could enhance GSK's product offerings and revenue in the oncology sector, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90